2005
Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. Journal Of Clinical Oncology 2005, 23: 5578-5587. PMID: 16009949, DOI: 10.1200/jco.2005.07.120.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCetuximabCisplatinDisease ProgressionDrug Administration ScheduleFemaleFluorouracilHead and Neck NeoplasmsHumansLogistic ModelsMaleMiddle AgedNeoplasm Recurrence, LocalPaclitaxelSurvival AnalysisTreatment OutcomeConceptsSquamous cell carcinomaSkin rashCell carcinomaAcne-like skin rashMulticenter phase II studyPhase II multicenter studyRefractory squamous cell carcinomaMedian overall survival timeEpidermal growth factor receptor antibody cetuximabRecurrent squamous cell carcinomaCisplatin/fluorouracilCisplatin/paclitaxelSafety of cetuximabPhase II studyMajority of patientsOverall survival timePlatinum-based therapySingle-agent trialsSerious allergic reactionsMurine monoclonal antibodiesActive regimenStable diseaseCommon toxicitiesII studyMedian duration
2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. PMID: 12422310, DOI: 10.1053/sonc.2002.35644.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activityIMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
Herbst R, Hong W. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. DOI: 10.1016/s0093-7754(02)70087-0.Peer-Reviewed Original ResearchSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activity